Piper Sandler analyst Christopher Raymond raised the firm’s price target on Ultragenyx (RARE) to $140 from $135 and keeps an Overweight rating on the shares following the announcement of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback